Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V. Shelton E, et al. Inflamm Bowel Dis. 2015 Dec;21(12):2879-85. doi: 10.1097/MIB.0000000000000561. Inflamm Bowel Dis. 2015. PMID: 26288002 Free PMC article.
Reply.
Shelton E, Ananthakrishnan AN. Shelton E, et al. Gastroenterology. 2017 Jan;152(1):306. doi: 10.1053/j.gastro.2016.11.037. Epub 2016 Nov 26. Gastroenterology. 2017. PMID: 27893976 No abstract available.
A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive.
Flanagan E, Wright EK, Sparrow MP, Moore GT, Connell WR, De Cruz P, Christensen B, Shelton E, Kamm MA, Ward MG, Dowling D, Brown S, Kashkooli S, Thompson AJ, Ross AL, Kiburg KV, Bell SJ. Flanagan E, et al. Among authors: shelton e. Inflamm Bowel Dis. 2021 Nov 15;27(12):1909-1918. doi: 10.1093/ibd/izab021. Inflamm Bowel Dis. 2021. PMID: 33704467
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort.
Varma P, Rajadurai AS, Holt DQ, Devonshire DA, Desmond CP, Swan MP, Nathan D, Shelton ET, Prideaux L, Sorrell C, Rusli F, Crantock LRF, Dev A, Ratnam DT, Pianko S, Moore GT. Varma P, et al. Intern Med J. 2019 Jun;49(6):753-760. doi: 10.1111/imj.14150. Intern Med J. 2019. PMID: 30381884
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
Schulberg JD, Wright EK, Holt BA, Hamilton AL, Sutherland TR, Ross AL, Vogrin S, Miller AM, Connell WC, Lust M, Ding NS, Moore GT, Bell SJ, Shelton E, Christensen B, De Cruz P, Rong YJ, Kamm MA. Schulberg JD, et al. Among authors: shelton e. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):318-331. doi: 10.1016/S2468-1253(21)00393-9. Epub 2021 Dec 8. Lancet Gastroenterol Hepatol. 2022. PMID: 34890567 Clinical Trial.
263 results